Reviva Pharmaceuticals Raises Funds for Schizophrenia Trial

Reviva Pharmaceuticals' stock has hit a 52-week low, falling over 60% in regular trading amid a proposed public offering.

The company aims to utilize approximately $10 million raised from its public offering to support its Phase 3 RECOVER-2 trial for schizophrenia, expected to launch in the first half of 2026, thereby advancing the development of its drug brilaroxazine. Following the public offering priced at $1.50 per share, Reviva's stock plummeted over 40% in pre-market trading, reflecting market pessimism regarding the company's outlook. Despite the stock decline, retail investor sentiment on Stocktwits shifted from neutral to bullish, indicating a divide in market perception.

The implications of this funding are significant as it highlights Reviva's commitment to advancing its clinical trials, although the sharp decline in stock price raises concerns about investor confidence and the company's ability to secure necessary funding.